The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
Collaboration aims to align hospital staff learning with NABH 6th Edition standards, patient safety, and measurable quality outcomes
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The license is valid for five years, effective from April 9, 2026
Subscribe To Our Newsletter & Stay Updated
